Icosagen completes €45M expansion with EIB loan to unify biologics under one roof
What's the deal? Estonia-based biotech IcosagenDealroom has a profile for this one. Try Dealroom → has finished a €45 million expansion, uniting protein discovery, development, and GMP manufacturing at a single site in Tartu.
The project drew an €18 million loan from the European Investment Bank, backed by the InvestEU program, with the rest from Icosagen's own funds.
The investment built a new single-use GMP manufacturing facility, compliant with European regulatory requirements.
Why now? Europe wants to cut its reliance on external manufacturing for complex biologics.
"Strengthening Europe's biotechnology value chain is essential for our competitiveness and resilience," said EIB Vice-President Karl Nehammer. The integrated model aims to help European innovators bring complex biologics to patients faster.
What could go wrong? Icosagen is betting on non-standard antibody and protein modalities that don't fit conventional platform approaches.
That bespoke focus carries technical risk, though the company argues that folding developability and manufacturability checks into early discovery reduces costly late-stage surprises.
The signal: The EIB's InvestEU-backed loan reflects a broader European push to onshore complex biologics capacity, channelling government finance toward homegrown contract research providers rather than relying on external manufacturers. For Icosagen, now a breakout-stage player with more than 200 scientists, the bet is that an integrated discovery-to-GMP model can carve out a niche serving the hard-to-make modalities that conventional platforms struggle to handle.
Read more: Biotech News Wire
Image credit: Generated with Gemini
